Cytotherapy
Publisher: Elsevier · ISSN 1465-3249 · 58 articles
- Aims and Scope
- Editorial Board
- Subscription information
- Table of Contents
- A regulatory gap: addressing visible particle control in cell and gene therapies through a risk-based framework
- Comparative analysis of advanced therapy regulatory frameworks in Latin America: perspectives from the ISCT South and Central America Legal and Regulatory Affairs Committee
- Swissmedic Innovation Office: early regulatory engagement to accelerate ATMP clinical development—regulatory insights and recommendations
- Enhanced antitumor efficacy through combined chimeric antigen receptor T cell therapy and CD40 stimulation in syngeneic solid tumor models
- Hypoxia during GPC2-CAR T-cell manufacturing compromises cell expansion and cytotoxic capacity
- Early detection of chimeric antigen receptor-T-associated neurotoxicity via cytokine monitoring in serum
- Pre-clinical validation of OSCAR-3 mRNA-based CAR T cells for targeting osteosarcomas
- Pretransplant infection associated with inferior survival after TCRαβ/CD19-depleted haploidentical HSCT in pediatric nonmalignant disorders
- Multi-site validation and applicability assessment of a practical three-dimensional colony formation assay for detecting malignantly transformed cells
- Evaluation of pluripotent stem cell-derived myeloid line-based chimeric antigen receptor macrophage-like cells identifies limited in vivo persistence
- Integrated T-cell enrichment, static transduction, and expansion in gas-permeable bioreactors for adoptive cell therapy
- Automating chimeric antigen receptor T-cell manufacturing across distinct platforms delivers similar cell quality, phenotype and function
- Phenotype-outcome standards must guide personalized CAR-T manufacturing
- Mesenchymal stromal cells for progressive multiple sclerosis: current evidence and translational challenges
- Cell therapies: are we doing enough to protect patients and address the barriers to patient access?
- Consensus perspectives on quality control and safety strategies for the clinical translation of induced pluripotent stem cell−derived cell therapies
- Model-predicted fludarabine exposure and outcomes after tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia
- Semi-automated manufacturing preserves memory-associated and metabolic features of piggyBac CAR-T cells
- Overcoming the bottleneck: CD3Predict tool to streamline and improve access to chimeric antigen receptor T-cell leukapheresis
- Three-dimensional mesenchymal stromal cell spheroids potently suppress neutrophil extracellular trap formation
- Building a Clinical-Grade Allogenic Adipose-Derived MSC Therapy for Epidermolysis Bullosa
- Trajectory clustering of longitudinal donor chimerism after pediatric hematopoietic stem cell transplantation for non-malignant disorders
- Calibrated prediction of CD34+ yield and apheresis product CD34+ concentration for allogeneic donor collection planning
- Large-particle T-cell activation improves manufacturability, reduces phagocytic loss and enhances chimeric antigen receptor-T cell cytotoxic function